As there is a continuous need for increased potency on weight loss, we investigated the pharmacological potential of combination therapy using the highly potent DACRA KBP-089 and the GLP-1 analog liraglutide for obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.